

Attorney Docket No.: 49673 (72024)
U.S.S.N.: 09/537,859
Filed: February 22, 2002
Amendment and Response to Final Office Action
Page 2 of 10

D1 variant (SEQ ID NO. 5). Signal ←

Amendment Directing Entry Of Sequence Listing

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (3 pages) and number the pages as appropriate.

In the Claims

Please cancel claims 13-23.

✓ Please add claims 24-30.

24. (New) An isolated amino-terminally truncated MCP-2 comprising residues 2-76 of an MCP-2 polypeptide according to SEQ ID NO: 2, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residue 1 and has chemokine antagonistic activity.
25. (New) An isolated amino-terminally truncated MCP-2 comprising residues 3-76 of an MCP-2 polypeptide according to SEQ ID NO: 2, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-2 and has chemokine antagonistic activity.
26. (New) An isolated amino-terminally truncated MCP-2 comprising residues 4-76 of an MCP-2 polypeptide according to MCP-2 (SEQ ID NO: 2), wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-3 and has chemokine antagonistic activity.

D2

Attorney Docket No.: 49673 (72024).

U.S.S.N.: 09/537,859

Filed: February 22, 2002

Amendment and Response to Final Office Action

Page 3 of 10

- D2
canceled
27. (New) An isolated amino-terminally truncated MCP-2 polypeptide comprising residues 5-76 of an MCP-2 polypeptide according to SEQ ID NO: 2 or 5, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residues 1-4 and has chemokine antagonistic activity.
 28. (New) The isolated amino-terminally truncated MCP-2 polypeptide of claims 24-27, wherein the truncated MCP-2 polypeptide is in glycosylated form.
 29. (New) A pharmaceutical composition comprising an isolated truncated MCP-2 polypeptide according to any one of claims 24-27, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
 30. (New) The pharmaceutical composition according to claim 29, wherein the isolated truncated MCP-2 polypeptide is in glycosylated form.

RESPONSE

Pending claims

Claims 13-23 are pending. Upon entry of this Amendment and Response, claims 13-23 are canceled and new claims 24-30 are presented for examination. Claims are canceled herein solely to expedite prosecution of the instant application and without prejudice to pursuing these claims in continuing and other related applications. Newly added claims recite truncations which may be derived from either allelic form of MCP-2 and which possess chemokine antagonistic activity. The newly added claims find support in the claims as originally filed and in the sequences provided.